Helena Cortez‐Pinto

University of Lisbon — Portugal

Medicine · Health Sciences

70h-index33.6kcitations304works11.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(225), Liver Disease and Transplantation(74), Diet, Metabolism, and Disease(61), Alcohol Consumption and Health Effects(56), Diet and metabolism studies(22)

Publications299 total

Impact of YAQ001 on the gut microbiome, permeability and markers of systemic inflammation in patients with cirrhosis
2025Open Access
Metabolic dysfunction-associated steatohepatic liver disease (MASLD): Exploratory analysis of metabolic risk factors, liver condition and effects of lifestyle intervention.
Clinical Nutrition ESPEN·2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Journal of Hepatology·2025· 7 citedOpen Access
OS-013 Optimizing non-invasive screening to reduce biopsy screen failure in clinical trials for metabolic dysfunction-associated steatotic liver disease
Journal of Hepatology·2025
TOP-394 Comprehensive analysis of biomarker performance targeting “advanced fibrosis” and “at-risk” metabolic-dysfunction associated steatotic liver disease (MASH) – primary analysis of the LITMUS study cohort
Journal of Hepatology·2025
SAT-373 Epidemiology, clinical presentation and management of Wilson’s disease in Portugal – data from a national registry
Journal of Hepatology·2025
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
Journal of Hepatology·2025· 2 cited
WED-489 Similar prevalence of MASLD and liver fibrosis when screening high-risk patients identified in primary care versus outpatient clinics in secondary care
Journal of Hepatology·2025
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study
BMJ Open·2025· 2 citedOpen Access
TOP-218 Yaq-001 positively impacts gut microbiome composition, virulence, antimicrobial resistance gene profile resulting in significant effects on ammonia, endotoxemia and inflammation in cirrhosis patients
Journal of Hepatology·2025Open Access
THU-421 10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort
Journal of Hepatology·2025
TOP-377 The “LITMUS metabolic-dysfunction associated steatotic liver disease intention-to-treat” (LiMITT) score: a machine learning proteomic tool to select patients for therapy
Journal of Hepatology·2025· 1 cited
THU-420 10 years progression of metabolic risk factors, diet quality and degree of steatosis and fibrosis in a general population cohort ECOR liver study
Journal of Hepatology·2025
Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis
Inflammatory Bowel Diseases·2025· 2 cited
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Digestive Diseases and Sciences·2025· 2 citedOpen Access
P0808 Early Top-down treatment improves transmural remission rates in Crohn's disease - a risk-adjusted propensity score matched analysis
Journal of Crohn s and Colitis·2025· 1 citedOpen Access
Prevalence of liver disease around the world
Elsevier eBooks·2025
Contributors
Elsevier eBooks·2025
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
JHEP Reports·2024· 61 citedOpen Access
Treat-to-Target in Inflammatory Bowel Disease: An Updated Survey of Treatment Strategies among Portuguese Gastroenterologists
GE Portuguese Journal of Gastroenterology·2024Open Access
page 1 of 15Next →

Frequent Co-authors

Quentin M. Anstee(16), Manuel Romero‐Gómez(14), Vincent Wai‐Sun Wong(12), Elisabetta Bugianesi(12), Vlad Ratziu(12), Jeffrey V. Lazarus(12), Mariana Verdelho Machado(11), Philip N. Newsome(10), Luca Valenti(10), Zobair M. Younossi(10), Sven Francque(10), Ramón Bataller(10), Jörn M. Schattenberg(9), Yusuf Yılmaz(9), Stephen A. Harrison(9), Jérôme Boursier(9), Shira Zelber‐Sagi(8), Marco Arrese(8), Mary E. Rinella(8), Christopher D. Byrne(8)